Skip to main content

Polygenic risk scores across the extended psychosis spectrum.

Translational psychiatry

Authors: Lukasz Smigielski, Sergi Papiol, Anastasia Theodoridou, Karsten Heekeren, Miriam Gerstenberg, Diana Wotruba, Roman Buechler, Per Hoffmann, Stefan Herms, Kristina Adorjan, Heike Anderson-Schmidt, Monika Budde, Ashley L Comes, Katrin Gade, Maria Heilbronner, Urs Heilbronner, Janos L Kalman, Farahnaz Klöhn-Saghatolislam, Daniela Reich-Erkelenz, Sabrina K Schaupp, Eva C Schulte, Fanny Senner, Ion-George Anghelescu, Volker Arolt, Bernhard T Baune, Udo Dannlowski, Detlef E Dietrich, Andreas J Fallgatter, Christian Figge, Markus Jäger, Georg Juckel, Carsten Konrad, Vanessa Nieratschker, Jens Reimer, Eva Reininghaus, Max Schmauß, Carsten Spitzer, Martin von Hagen, Jens Wiltfang, Jörg Zimmermann, Anna Gryaznova, Laura Flatau-Nagel, Markus Reitt, Milena Meyers, Barbara Emons, Ida Sybille Haußleiter, Fabian U Lang, Thomas Becker, Moritz E Wigand, Stephanie H Witt, Franziska Degenhardt, Andreas J Forstner, Marcella Rietschel, Markus M Nöthen, Till F M Andlauer, Wulf Rössler, Susanne Walitza, Peter Falkai, Thomas G Schulze, Edna Grünblatt

As early detection of symptoms in the subclinical to clinical psychosis spectrum may improve health outcomes, knowing the probabilistic susceptibility of developing a disorder could guide mitigation measures and clinical intervention. In this context, polygenic risk scores (PRSs) quantifying the additive effects of multiple common genetic variants hold the potential to predict complex diseases and index severity gradients. PRSs for schizophrenia (SZ) and bipolar disorder (BD) were computed using Bayesian regression and continuous shrinkage priors based on the latest SZ and BD genome-wide association studies (Psychiatric Genomics Consortium, third release). Eight well-phenotyped groups (n = 1580; 56% males) were assessed: control (n = 305), lower (n = 117) and higher (n = 113) schizotypy (both groups of healthy individuals), at-risk for psychosis (n = 120), BD type-I (n = 359), BD type-II (n = 96), schizoaffective disorder (n = 86), and SZ groups (n = 384). PRS differences were investigated for binary traits and the quantitative Positive and Negative Syndrome Scale. Both BD-PRS and SZ-PRS significantly differentiated controls from at-risk and clinical groups (Nagelkerke's pseudo-R: 1.3-7.7%), except for BD type-II for SZ-PRS. Out of 28 pairwise comparisons for SZ-PRS and BD-PRS, 9 and 12, respectively, reached the Bonferroni-corrected significance. BD-PRS differed between control and at-risk groups, but not between at-risk and BD type-I groups. There was no difference between controls and schizotypy. SZ-PRSs, but not BD-PRSs, were positively associated with transdiagnostic symptomology. Overall, PRSs support the continuum model across the psychosis spectrum at the genomic level with possible irregularities for schizotypy. The at-risk state demands heightened clinical attention and research addressing symptom course specifiers. Continued efforts are needed to refine the diagnostic and prognostic accuracy of PRSs in mental healthcare.

© 2021. The Author(s).

PMID: 34836939

Participating cluster members